CSF3R/CD114: Um preditor relacionado à pior sobrevida nos gliomas
Barra lateral de artigos
Conteúdo do artigo principal
Resumo
Introdução: Os gliomas são os tumores cerebrais primários mais frequentes, representando mais de 80% de todas as neoplasias primárias do sistema nervoso central. Esses tumores são classificados em diferentes subtipos histológicos, sendo os principais o astrocitoma, o oligodendroglioma e o glioblastoma. Dentre eles, o glioblastoma destaca-se como o subtipo mais comum e agressivo, associado a prognóstico reservado, mesmo diante de abordagens terapêuticas multimodais que combinam ressecção cirúrgica, radioterapia e quimioterapia com temozolomida
Objetivo: Analisar a associação da expressão de CD114 com a sobrevida em pacientes com glioma.
Método: Os artigos foram selecionados por meio de busca nas seguintes bases de dados: Biblioteca Virtual em Saúde (BVS), Medline, PubMed e SciELO. Os descritores utilizados foram “CSF3R, CD114, fator estimulador de colônias de granulócitos, glioma, glioblastoma, tumor cerebral”, realizando busca avançada combinando-os com o operador booleano AND.
Resultado: Foram analisados 95 artigos.
Conclusão: Existe associação entre a alta expressão de CSF3R/CD114 e o pior prognóstico dos pacientes, refletido pela redução da sobrevida global em diferentes tipos de tumores gliais.
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507. doi: https://doi.org/10.1056/NEJMra0708126
Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402-9. doi: https://doi.org/10.1200/jco.2017.73.0119
Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, et al. Pediatric glioma: An update of diagnosis, biology, and treatment. Cancers (Basel). 2021;13(4):758. doi: https://doi.org/10.3390/cancers13040758
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella?Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021;23(8):1231-51. doi: https://doi.org/10.1093/neuonc/noab106
Hardigan AA, Jackson JD, Patel AP. Surgical management and advances in the treatment of glioma. Semin Neurol. 2023;43(6):810-24. doi: https://doi.org/10.1055/s-0043-1776766
Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G?CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Investig. 2005;115:2083?98. https://doi.org/10.1172/jci23559
Zage PE, Whittle SB, Shohet JM. CD114: a new member of the neural crest?derived cancer stem cell marker family. J Cell Biochem. 2017;118:221-31. doi: https://doi.org/10.1002/jcb.25656
Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, et al. G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. Cancer Res. 2015;75;(12):2566-79. doi: https://doi.org/10.1158/0008-5472.can-14-2946
Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, Chen Z, et al. G?CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy?resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013;73(13):4134-46. https://doi.org/10.1158/0008-5472.can-12-4056
Zhang L, Agarwal S, Shohet JM, Zage PE. CD114 expression mediates melanoma tumor cell growth and treatment resistance. Anticancer Res. 2015;35(7):3787-92.
Mueller MM, Herold?Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE. Autocrine growth regulation by granulocyte colony?stimulating factor and granulocyte?macrophage colony?stimulating factor in human gliomas with tumor progression. Am J Pathol. 1999;155(5):1557-67. doi: https://doi.org/10.1016/S0002-9440(10)65472-7
Kyo S, Kanaya T, Takakura M, Inoue M. A case of cervical cancer with aggressive tumor growth: Possible autocrine growth stimulation by G?CSF and IL?6. Gynecol Oncol. 2000;78(Pt 1):383-7. doi: https://doi.org/10.1006/gyno.2000.5904
Hirai K, Kumakiri M, Fujieda S, Sunaga H, Lao LM, Imamura Y, et al. Expression of granulocyte colony?stimulating factor and its receptor in epithelial skin tumors. J Dermatol Sci. 2001;25(3):179-88. https://doi.org/10.1016/s0923- 1811(00)00131-6
Savarese TM, Mitchell K, McQuain C, Campbell CL, Guardiani R, Wuu J, et al. Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett. 2001;162(1):105‑15. https://doi.org/10.1016/s0304-3835(00)00623-6"
Chakraborty A, Guha S. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology. 2007;69(6):1210-5. doi: https://doi.org/10.1016/j.urology.2007.02.035
Hanumanthu VS, Pirruccello SJ. GCSF?R expression in myelodysplastic and myeloproliferative disorders and blast dysmaturation in CML. Am J Clin Pathol. 2013;140(2):155-64. doi: https://doi.org/10.1309/AJCPCLHZR5KUHUBM
Paul SR, Huo Y, Liu A, Lesperance J, Garancher A, Wechsler-Reya RJ, et al. Characterization of G?CSF receptor expression in medulloblastoma. Neurooncol. 2020;2(1):vdaa062. https://doi.org/10.1093/noajnl/vdaa062
Monteiro JM, Reis Ramos JI, Teixeira e Sousa I, Bighetti?Trevisan RL, Ribas- Filho JM, Isolan GR. Identification of CD114 membrane receptors as a molecular target in medulloblastomas. Int J Mol Sci. 2023;24(6):5331. doi: https://doi.org/10.3390/ijms24065331
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781-90. https://doi.org/10.1056/nejmoa1214514
Maxson JE, Ries RE, Wang YC, Gerbing RB, Kolb EA, Thompson SL, et al. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood. 2016;127(24):3094-98. https://doi.org/10.1182/blood- 2016-04-709899
Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, et al. Neuronal activity promotes glioma growth through neuroligin?3 secretion. Cell. 2015;161(4):803-16. doi: https://doi.org/10.1016/j.cell.2015.04.012
Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019;573(7775):539-45. doi: https://doi.org/10.1038/s41586-019-1563-y
Pinheiro KV, Thomaz A, Souza BK, Metcalfe VA, Freire NH, Brunetto AT, de Farias CB, et al. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma. Mol Biol Rep. 2020;47:6817-28. https://doi.org/10.1007/s11033- 020-05739-2
Thomaz A, Jarger M, Brunett AL, Brunetto AT, Gregianin L, de Farias CB, et al. Neurotrophin signaling in medulloblastoma. Cancers. 2020;12(9):2542. doi: https://doi.org/10.3390/cancers12102542
Krsna S, Choudhury A, Keough MB, Seo K, Ni L, Kakaizada S, et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature. 2023;617(7961):599-607. doi: https://doi.org/10.1038/s41586-023-06036-1
Rodrigues EM, Giovanini AF, Ribas CAPM, Malafaia O, Roesler R, Isolan GR. The nervous system development regulator neuropilin?1 as a potential prognostic marker and therapeutic target in brain cancer. Cancers. 2023;15(20):4922. https://doi.org/10.3390/cancers15204922
Wallner S, Peters S, Pitzer C, Resch H, Bogdahn U, Schneider A. The granulocyte?colony stimulating factor has a dual role in neuronal and vascular plasticity. Front Cell Dev Biol. 2015;3:48. doi: https://doi.org/10.3389/fcell.2015.00048
Su Y, Cui L, Piao C, Li B, Zhao LR. The effects of hematopoietic growth factors on neurite outgrowth. PLoS One. 2013;8(10):e75562. doi: https://doi.org/10.1371/journal.pone.0075562
He J, Russell T, Qiu X, Hao F, Kyle M, Chin L, et al. The contribution of stem cell factor and granulocyte colony‑stimulating factor in reducing neurodegeneration and promoting neurostructure network reorganization after traumatic brain injury. Brain Res. 2020;1746:147000.doi: https://doi.org/10.1016/j.brainres.2020.147000"
Beckhauser AP, Nisihara RM, Tonial AF, Nassif PAN, dos Santos CEO, Lages Neto M, et al. O papel da obesidade (e da perda de peso pela cirurgia bariátrica) nas doenças autoimunes. BioSCIENCE. 2024;82:e032
Hou L, Tian L, Li J, Zhang Z, Han X, Zhou H, et al. Systematic Analysis of an Immune-Related Gene Signature for Predicting Prognosis and Immune Characteristics in Primary Lower Grade Glioma. Biomed Res Int. 2025:2025:6180391. https://doi.org/10.1155/bmri/6180391
Jov?evska I. Genetic secrets of long-term glioblastoma survivors. Bosn J Basic Med Sci. 2019;19(2):116-24. https://doi.org/10.17305/bjbms.2018.3717
Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: A review. JAMA Oncol. 2022;8(10):1493-501. doi: https://doi.org/10.1001/jamaoncol.2022.2844
Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. JPathol. 2014;232(2):165-77. https://doi.org/10.1002/path.4282
Noroxe DS, Poulsen HS, Lassen U. Hallmarks of glioblastoma: a systematic review. ESMO. 2016;1:e000144. http://doi.org/10.1136/esmoopen-2016-000144
de Oliveira LBC, Malafaia O, Tabushi FS, Carvalhal SRS, Ioshii SO, Schuh R, et al. Análise de citocinas e CD68 na aorta: novos parâmetros para estudo da inflamação no diabete melito tipo 2. BioSCIENCE. 2025;83(S2):e00023
Roda D, Veiga P, Melo JB, Carreira IM, Ribeiro IP. Principles in the management of glioblastoma. Genes (Basel). 2024;15(4):501. doi: https://doi.org/10.3390/genes15040501
Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2(9):494?503. https://doi.org/10.1038/ncpneuro0289
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96. doi: https://doi.org/10.1056/NEJMoa043330
Bao J, Sun R, Pan Z, Wei S. Current chemotherapy strategies for adults with IDH-wildtype glioblastoma. Front Oncol. 2024;14:1438905. doi: https://doi.org/10.3389/fonc.2024.1438905
Ippen FM, Scherm A, Kessler T, Hau P, Agkatsev S, Baurecht H, et al. Targeted agents in patients with progressive glioblastoma-a systematic meta-analysis of randomized clinical trials. Cancer Med. 2024;13(12):e7362. https://doi.org/10.1002/cam4.7362
Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004;3(5):430-46. https://doi.org/10.1038/nrd1380
Tang J, Karbhari N, Campian JL. Therapeutic targets in glioblastoma: molecular pathways, emerging strategies, and future directions. Cells. 2025;14(7):494. doi: https://doi.org/10.3390/cells14070494
Bae WH, Maraka S, Daher A. Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration. Front Oncol. 2024;14:1441460. doi: https://doi.org/10.3389/fonc.2024.1441460
Jacome MA, Wu Q, Pina Y, Erame AB. Evolution of molecular biomarkers and precision molecular therapeutic strategies in glioblastoma. Cancers (Basel). 2024;16(21):3635. https://doi.org/10.3390/cancers16213635
Tataranu LG, Turliuc S, Kamel A, Rizea RE, Dricu A, Staicu GA, et al. Glioblastoma tumor microenvironment: an important modulator for tumoral progression and therapy resistance. Curr Issues Mol Biol. 2024;46(9):9881-94. doi: https://doi.org/10.3390/cimb46090588
Stoyanov GS, Dzhenkov DL. On the Concepts and History of Glioblastoma Multiforme - Morphology, Genetics and Epigenetics. Folia Med (Plovdiv). 2018;60(1):48-66. https://doi.org/10.1515/folmed-2017-0069
Martin?Villalba A, Okuducu AF, von Deimling A. The evolution of our understanding on glioma. Brain Pathol. 2008;18(3):455-63. https://doi.org/10.1111/j.1750-3639.2008.00136.x
Reiman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102(13):932-41. https://doi.org/10.1093/jnci/djq187
Sardeto GA, Boss LEC, Pacheco MJR. O impacto da obesidade nos resultados pós-operatórios de operações abdominais.BioSCIENCE. 2024;82:e042
Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009;115(15):3512-8. doi: https://doi.org/10.1002/cncr.24406
Gal O, Mehta MP, Kotecha R. Radiotherapeutic advances in the management of glioblastoma.J Neurooncol. 2024;170(3):509–20. doi: https://doi.org/10.1007/s11060-024-04824-x"
Inggas MAM, Patel U, Wijaya JH, Otinashvili N, Menon VR, Iyer AK, et al. The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis. BMC Cancer. 2025;25(1):399. https://doi.org/10.1186/s12885-025-13757-1
Minniti G, de Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. JNeurooncol. 2008;88(1):97–103. https://doi.org/10.1007/s11060-008-9538-0"
Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, et al. Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1460-9. doi: https://doi.org/10.1001/jamaoncol.2016.1373
Nagae LM, Pinho M da C, Funari MB de G. Tractography. Einstein. 2010; 8(2 Pt 1):252-3. https://doi.org/10.1590/S1679-45082010AI1112
Gerritsen JKW, Broekman MLD, de Vleeschouwer S, Schucht P, Nahed BV, Berger MS, et al. Safe surgery for glioblastoma: Recent advances and modern challenges. Neurooncol Pract. 2022;9(5):364–79. doi: https://doi.org/10.1093/nop/npac019"
Revilla‑Pacheco F, Rodríguez-Salgado P, Barrera-Ramírez M, Morales-Ruiz MP, Loyo-Varela M, Rubalcava-Ortega J, et al. Extent of resection and survival in patients with glioblastoma multiforme: systematic review and meta‑analysis. Medicine (Baltimore).2021;100(25):e26432. https://doi.org/10.1097/md.0000000000026432
Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3?8. https://doi.org/10.3171/2011.2.jns10998
Parisi S, Corsa P, Raguso A, Perrone A, Cossa S, Munafo T, et al. Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. Biomed Res Int. 2015;2015:620643. doi: https://doi.org/10.1155/2015/620643
Zhao Y, Wu J, Shi L. Adjuvant temozolomide for the treatment of glioblastoma: a meta?analysis of randomized controlled studies. Clin Neuropharmacol. 2021;44(4):132-7. doi: https://doi.org/10.1097/WNF.0000000000000449
Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4(1):17-43. doi: https://doi.org/10.20517/cdr.2020.79
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-8. doi: https://doi.org/10.1038/nature07385
Politis A, Stavrinou L, Kalyvas A, Boviatsis E, Piperi C, et al. Glioblastoma: molecular features, emerging molecular targets and novel therapeutic strategies. Crit Rev Oncol Hematol. 2025;104764. https://doi.org/10.1016/j.critrevonc.2025.104764"
Roesler R, Brunetto AT, Abujamra AL, de Farias CB, Brunetto AL, Schwartsmann G. Current and emerging molecular targets in glioma. Expert Rev Anticancer Ther. 2010;10(11):1735?51. https://doi.org/10.1586/era.10.167
An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37(12):1561-75. doi: https://doi.org/10.1038/s41388-017-0045- 7
Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-77. doi: https://doi.org/10.1016/j.cell.2013.09.034
Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10(5):319-31. https://doi.org/10.1038/nrc2818
Ismailov A, Spallone A, Belogurov-Jr A, Herbert A, Poptsova M. Molecular biology of the deadliest cancer ? glioblastoma: what do we know? Front Immunol. 2025;16:1530305. https://doi.org/10.3389/fimmu.2025.1530305
Lan Z, Li X, Zhang X. Glioblastoma: an update in pathology, molecular mechanisms and biomarkers. Int J Mol Sci. 2024;25(2):3040. doi: https://doi.org/10.3390/ijms25023040
Zhang Y, Dube C, Gibert-Jr M, Cruickshanks N, Wang B, Coughlan M, et al. The p53 Pathway in Glioblastoma. Cancers (Basel). 2018;10(9):297. https://doi.org/10.3390/cancers10090297
Ushio Y, Tada K, Shiraishi S, Kamiryo T, Shinojima N, Kochi M, et al. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci. 2003;8:e281-8. https://doi.org/10.2741/865
Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38-51. https://doi.org/10.1038/nrc1779
Lucchini S, Constantinou M, Marino S. Unravelling the mosaic: Epigenetic diversity in glioblastoma. Mol Oncol. 2024;18(12):2871-89. doi: https://doi.org/10.1002/1878-0261.13706
Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921-5. doi: https://doi.org/10.1016/j.cub.2020.06.081
Truffi M, Sorrentino L, Corsi F. Fibroblasts in the tumor microenvironment. Adv Exp Med Biol. 2020;1234:15-29. doi: https://doi.org/10.1007/978-3-030-04414- 0_2
Robinson SD, Filippopoulou C, Besta S, Samuels M, Betrán AL, Ajamieh MA, et al. Spatial biology - unravelling complexity within the glioblastoma microenvironment. Trends Mol Med. 2025;25:S1471?4914(25):00014?0. doi: https://doi.org/10.1016/j.molmed.2025.01.014
Tataranu LG, Turliuc S, Rizea RE, Dricu A, Alexandru O, Staicu GA, et al. A synopsis of biomarkers in glioblastoma: past and present. Curr Issues Mol Biol. 2024;46(7):6903-39. doi: https://doi.org/10.3390/cimb46070412
Abdullah KG, Adamson C, Brem S. The molecular pathogenesis of glioblastoma. Glioblastoma. 2017:21-31. https://doi.org/10.1016/B978-0-323-47660-7.00003-3
Ghosh N, Chatterjee D, Datta A. Tumor heterogeneity and resistance in glioblastoma: the role of stem cells. Apoptosis. 2025. doi: https://doi.org/10.1007/s10495-025-02123-y
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401. doi: https://doi.org/10.1038/nature03128
Kumar A, Vashishta M, Long L, Wu X, Lu JJ, Guha C, et al. The role of Notch, Hedgehog, and Wnt signaling pathways in the resistance of tumors to anticancer therapies. Front Cell Dev Biol. 2021;9:e650772. doi: https://doi.org/10.3389/fcell.2021.650772
Park SD, Saunders AS, Reidy MA, Bender DE, Clifton S, Morris KT. A review of granulocyte colony?stimulating factor receptor signaling and regulation with implications for cancer. Front Oncol. 2022;12:932608. https://doi.org/10.3389/fonc.2022.932608
Sarkala HB, Jahanshahi M, Dolatabadi LK, Namavar MR. G?CSF improved the memory and dendritic morphology impairments in the hippocampal CA1 pyramidal neurons after brain ischemia in male rats. Metab Brain Dis. 2023;38(8):2573?81. https://doi.org/10.1007/s11011-023-01286-4
Song S, Wang X, Sava V, Weeber EJ, Sanchez-Ramos J. In vivo administration of granulocyte colony?stimulating factor restores long?term depression in hippocampal slices prepared from transgenic APP/PS1 mice. J Neurosci Res. 2014;92(8):975-80. https://doi.org/10.1002/jnr.23378
Ahsan H, Asghar M, Malik SI. Potential diagnostic and drug target markers in glioblastoma. Sci Rep. 2024;14(1):7292. https://doi.org/10.1038/s41598-024- 57752-1
Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009;27(10):2383-92. https://doi.org/10.1002/stem.185
Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro Oncol. 2022;24(Suppl 5):v1- v95. https://doi.org/10.1093/neuonc/noac202
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66. https://doi.org/10.1016/s1470-2045(09)70025-7
Sareen H, Ma Y, Becker TM, Roberts TL, de Souza P, Powter B. Molecular biomarkers in glioblastoma: a systematic review and meta?analysis. Int J Mol Sci. 2022;23(16):8835. https://doi.org/10.3390/ijms23168835
Alghamri MS, McClellan BL, Avvari RP, Thalla R, Carney S, Hartlage CS, et al. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci Adv. 2021;7(40):eabh3243. doi: https://doi.org/10.1126/sciadv.abh3243
Masliantsev K, Pinel B, Balbous A, Guichet PO, Tachon G, Milin S, et al. Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome. Oncotarget. 2017;9(3):3968-79.https://doi.org/10.18632/oncotarget.23374
Im CN, Yun HH, Song B, Youn DY, Cui MN, Kim HS, et al. BIS?mediated STAT3 stabilization regulates glioblastoma stem cell?like phenotypes. Oncotarget. 2016;7(23):35056-70. doi: https://doi.org/10.18632/oncotarget.9039
De la Iglesia N, Konopka G, Lim KL, Nutt CL, Bromberg JF, Frank DA, et al. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci. 2008;28(23):5870-8. doi: https://doi.org/10.1523/JNEUROSCI.5387-07.2008
Luwor RB, Stylli SS, Kaye AH. The role of Stat3 in glioblastoma multiforme. J Clin Neurosci. 2013;20(7):907-11. https://doi.org/10.1016/j.jocn.2013.03.006